Promising new eczema drug for teens enters final testing phase

NCT ID NCT07042126

First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study tests a new medication called 611 in Chinese teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). The drug aims to reduce skin redness, itching, and rash by blocking a protein involved in inflammation. Participants will receive either 611 or a placebo, and doctors will measure improvements in skin symptoms over 16 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

    RECRUITING

    Nanchang, Zhejiang, 310003, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Fourth Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Jinhua, Zhejiang, 322000, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.